Abiomed Investor Relations Material
Latest events
Q1 2023
Abiomed
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Abiomed Inc
Access all reports
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It provides Impella 2.5 system, a percutaneous micro heart pump with integrated motor and sensors for use by interventional cardiologists to treat patients in cardiogenic shock; Impella CP system which enables physicians to treat patients needing circulatory support; Impella 5.0 system that provides left ventricular support; and Impella LD heart pump for use in high risk percutaneous coronary interventions.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
ABMD
Country
🇺🇸 United States